GUIDO RASI

Professore Ordinario

Università degli Studi di Roma La Sapienza

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Collaborators (5)

CLAUDIA MATTEUCCI

University of Rome Tor Vergata

Rick Vreman

Utrecht University

emanuela balestrieri

University of Rome Tor Vergata

SANDRO GRELLI

Università degli Studi di Roma La Sapienza

Nicola Toschi

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

GUIDO RASI

Research Interests

Explore related searches

Contact this professor

Articles (16)

Collaborators (5)

CLAUDIA MATTEUCCI

Rick Vreman

emanuela balestrieri

SANDRO GRELLI

Nicola Toschi

Make your next move.

GUIDO RASI

Research Interests

Explore related searches

Contact this professor

Articles (16)

Preliminary Evidence of the Differential Expression of Human Endogenous Retroviruses in Kawasaki Disease and SARS-CoV-2-Associated Multisystem Inflammatory Syndrome in Children

Persistence of circulating CD169+monocytes and HLA-DR downregulation underline the immune response impairment in PASC individuals: the potential contribution of different COVID-19 pandemic waves.

Expression profile of HERVs and inflammatory mediators detected in nasal mucosa as a predictive biomarker of COVID-19 severity.

Safety of COVID-19 vaccines.

A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems.

Legends of allergy and immunology: Sergio Bonini

Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements

High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients

High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients

Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements.

Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation

Big Data - How to Realize the Promise

Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?

Clinical trial publications: A sufficient basis for healthcare decisions?

Pharmacovigilance 2030 Invited Commentary for the January 2020 "Futures" Edition of Clinical Pharmacology and Therapeutics

Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth

Collaborators (5)

CLAUDIA MATTEUCCI

Rick Vreman

emanuela balestrieri

SANDRO GRELLI

Nicola Toschi

Make your next move.